Das M, Musetti S, Huang L. RNA interference-based cancer drugs: the roadblocks, and the "delivery" of the promise. Nucleic Acid Ther. 2019 Apr;29(2):61-6. doi: 10.1089/nat.2018.0762
Trask PC, Mitra D, Iyer S, Candrilli SD, Kaye JA. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol. 2012 May 1;95(5):535-44.
Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol. 2012 Mar 1;95(3):263-73.
Lang K, Meyers JL, Korn JR, Lee S, Sikirica M, Crivera C, Dirani R, Menzin J. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv. 2010 Dec 1;61(12):1239-47.
Pelletier SJ, Fu S, Thyagarajan (Hoffman) V, Romero-Marrero C, Batheja MJ, Punch JD, Magee JC, Lok AS, Fontana RJ, Marrero JA. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl Surg. 2009 Aug;15(8):859-68. doi: 10.1002/lt.21778
Dorazio P, Keininger DL, Abetz L, Coombs JH, Copley-Merriman K, Bury-Maynard DP, Hsu MA. Comparing patient and nurse perspectives on cancer treatment: results from a qualitative study. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; September 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 Sep; 22:778.
Coombs JH, Abetz L, Keininger DL, Earle CC, Copley-Merriman K, Hsu M-A, Bury-Maynard DP. Development of the Cancer Chemotherapy Satisfaction Questionnaire (CCSQ): part I: item-generation and content validity testing. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:545.
Clark M, Copley-Merriman K, Coombs JH, Von Pawel J, Koschel G, Pauer LR. Patient reported outcomes (symptoms, functioning, and quality of life [QOL]) in a randomized Phase II study of CI-994 plus carboplatin and paclitaxel (C/T) vs placebo (PBO) plus C/T in the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC). Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:687.